Abstract:We herein report a new series of indole‐tethered pyrazoline derivatives as potent anticancer agents. A total of 12 compounds were designed and synthesized by conventional as well as microwave‐irradiated synthesis methods. The latter method results in a significant reduction in the duration of reaction along with improved yields. All synthesized derivatives (7a−7l) were evaluated for their cytotoxic activity against A431, HeLa, and MDAMB‐231 cell lines. Compounds 7a and 7b were found most potent in the series and demonstrated an IC50 value of 3.17 and 5.16 µM against the A431 cell line, respectively, compared to the standard drug doxorubicin. Compounds 7a and 7b significantly suppress colony formation, migration, and S phase cell cycle arrest of A431 cells. Furthermore, compound 7a regulated the expression of apoptotic proteins causing the downregulation of procaspase 3/9, antiapoptotic protein Bcl‐xL, and upregulation of proapoptotic protein Bax in a dose‐dependent manner. Topoisomerase enzyme inhibition assay confirmed that compounds 7a and 7b can significantly inhibit topoisomerase IIα. In vivo oral acute toxicity of compounds 7a and 7b revealed that both compounds are safe compared to doxorubicin; cardiomyopathy studies showed normal architecture of cardiomyocytes and myofibrils. In addition, molecular docking studies revealed the possible interaction of compounds 7a and 7b within the active binding site of the topoisomerase enzyme. The 100 ns molecular dynamic simulation of compounds 7a and 7b proved that both compounds validate all screening parameters.

Precursor-Directed Generation of Indolocarbazoles with Topoisomerase IIα Inhibitory Activity

One New Indolocarbazole Alkaloid from the Streptomyces Sp. A22

Bioactive Indolocarbazoles from the Marine-Derived Streptomyces Sp DT-A61

Cytotoxic indolocarbazoles alkaloids from the streptomyces sp. A65

Discovery of Indolo[3,2- c]isoquinoline Derivatives as Novel Top1/2 Dual Inhibitors with Orally Efficacious Antitumor Activity and Low Toxicity

New 3-[(4-hydroxy-6-methly-2(1h)-pyridinones)-3-yl]-4-substituted-(1h)1,2,4- Triazole-5-Thiones: Efficient Synthesis, X-Ray Crystallographic Analysis, and Antitumor Activity

Identification, Structure–Activity Relationships of Marine-Derived Indolocarbazoles, and a Dual PKCθ/δ Inhibitor with Potent Antipancreatic Cancer Efficacy

Cytotoxic Indolocarbazoles From a Marine-Derived Streptomyces Sp. OUCMDZ-5380

Synthesis and biological evaluation of indeno[1, 2-b]indole derivatives as dual topoisomerase Ⅰ & Ⅱ inhibitors: novel multidrug resistant reversal anticancer agents

Design, Synthesis and Biological Activity of Pyrazolo[3,4-d]pyrimidine Derivatives Containing Indole Moiety

Synthesis and Biological Evaluation of Novel Pyrazoline Derivatives Containing Indole Skeleton As Anti-Cancer Agents Targeting Topoisomerase II.

Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-pyridone Type II DNA Topoisomerase Inhibitors Active Against Multidrug Resistant Gram-negative Bacteria

Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors

Palindromic carbazole derivatives: unveiling their antiproliferative effect via topoisomerase II catalytic inhibition and apoptosis induction

Selective and effective anticancer agents: Synthesis, biological evaluation and structure–activity relationships of novel carbazole derivatives

Efficient assembly and anti-tumor evaluation of novel polycyclic [1,2-a]-fused indoles

Total Synthesis of Indolocarbazole Alkaloid ZHD-0501 and its Seven Isomers

Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships

Design, Synthesis And Biological Evaluation Of Of Novel Anticancer Agent Tert-Butyl 1-Phenyl-3,4-Dihydro-1h-Pyrido[3,4-B]Indole-2(9h)-Carboxylate

Design, Synthesis and Biological Activity Evaluation of β-Carboline Derivatives Containing Nitrogen Heterocycles

Synthesis, biological evaluation, and in silico studies of indole‐tethered pyrazoline derivatives as anticancer agents targeting topoisomerase IIα